GUIDELINES IN DERMATOLOGY

gdkapak

SCLEROSING DISEASES OF THE SKIN

Sevim Baysak1
İlkin Zindancı2

1Haydarpasa Numune Training and Research Hospital, Department of Dermatology and Venereology, İstanbul, Türkiye
2Haydarpasa Numune Training and Research Hospital, Department of Dermatology and Venereology, İstanbul, Türkiye

Baysak S, Zindancı İ. Sclerosing Diseases of the Skin. In: Kutlubay Z, editor. Guidelines in Dermatology. 1st ed. Ankara: Türkiye Klinikleri; 2025. p.275-284.

ABSTRACT

Sclerosing skin diseases generally include dermatological conditions that manifest themselves in different clinical subtypes according to the effects of the skin and extracutaneous organs, include many different disease types such as systemic sclerosis, localized scleroderma and scleredema, and cause fibrotic changes in the skin, which can sometimes be difficult to distinguish from each other. There is accumulation of excessive amounts of extracellular matrix (ECM) components in the dermis or subcutaneous tissue, and their common clinical features are generally hardening of the skin, thickening of the skin and their tendency to adhere tightly to the underlying fascia. Although they have sclerosis as a common feature, other histopathological features such as the depth of sclerosis, hyalinization, mucin accumulation, sclerotic bodies, and fibroblastic proliferation, may indicate a more specific diagnosis.

Keywords: Scleroderma, localized; Scleroderma, systemic; Scleromyxedema; Scleredema adultorum

Referanslar

  1. Distler O, Cozzio A. Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy. Semin Immunopathol. 2016;38(1):87-95. [Crossref]  [PubMed]
  2. Eckes B, Moinzadeh P, Sengle G, Hunzelmann N, Krieg T. Molecular and cellular basis of scleroderma. Journal of molecular medicine. 2014;92:913-24. [Crossref]  [PubMed]
  3. Elhai M, Avouac J, Kahan A, Allanore Y. Systemic sclerosis: recent insights. Joint Bone Spine. 2015;82(3):148-53. [Crossref]  [PubMed]
  4. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. The Journal of clinical investigation. 2007;117(3):557-67. [Crossref]  [PubMed]  [PMC]
  5. Moinzadeh P, Aberer E, Ahmadi-Simab K, Blank N, Distler JH, Fierlbeck G, et al. Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis. Annals of the rheumatic diseases. 2015;74(4):730-7. [Crossref]  [PubMed]  [PMC]
  6. Loeys B, Gerber E, Riegert-Johnson D, Iqbal S, Whiteman P, McConnell V, et al. Mutations in fibrillin-1 cause congenital scleroderma: stiff skin syndrome. Science translational medicine. 2010;2(23):23ra0-ra0. [Crossref]  [PubMed]  [PMC]
  7. Gerber EE, Gallo EM, Fontana SC, Davis EC, Wigley FM, Huso DL, et al. Integrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma. Nature. 2013;503(7474):126-30. [Crossref]  [PubMed]  [PMC]
  8. Zulian F, Athreya B, Laxer R, Nelson A, Feitosa de Oliveira S, Punaro M, et al. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology. 2006;45(5):614-20. [Crossref]  [PubMed]
  9. Ferreli C, Gasparini G, Parodi A, Cozzani E, Rongioletti F, Atzori L. Cutaneous manifestations of scleroderma and scleroderma-like disorders: a comprehensive review. Clinical reviews in allergy & immunology. 2017;53:306-36. [Crossref]  [PubMed]
  10. Fett N, Werth VP. Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. Journal of the American Academy of Dermatology. 2011;64(2):217-28. [Crossref]  [PubMed]
  11. Silman A, Jannini S, Symmons D, Bacon P. An epidemiological study of scleroderma in the West Midlands. Br J Rheumatol. 1988;27(4):286-290. [Crossref]  [PubMed]
  12. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J. 2004;18(7):816-827. [Crossref]  [PubMed]
  13. Kreuter A, Hyun J, Skrygan M, et al. Ultraviolet A1-induced downregulation of human beta-defensins and interleukin-6 and interleukin-8 correlates with clinical improvement in localized scleroderma. Br J Dermatol. 2006;155(3):600-607. [Crossref]  [PubMed]
  14. Yamamoto T. Chemokines and chemokine receptors in scleroderma. International archives of allergy and immunology. 2006;140(4):345-56. [Crossref]  [PubMed]
  15. Gambichler T, Skrygan M, Labanski AA, Kolios AG, Altmeyer P, Kreuter A. Significantly increased CCL5/RANTES and CCR7 mRNA levels in localized scleroderma. Regulatory peptides. 2011;170(1-3):4-6. [Crossref]  [PubMed]
  16. Rongioletti F, Ferreli C, Atzori L, Bottoni U, Soda G. Scleroderma with an update about clinico-pathological correlation. Giornale italiano di dermatologia e venereologia: organo ufficiale, Societa italiana di dermatologia e sifilografia. 2018;153(2):208-15. [Crossref]  [PubMed]
  17. Knobler R, Moinzadeh P, Hunzelmann N, Kreuter A, Cozzio A, Mouthon L, et al. European Dermatology Forum S1‐guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes. Journal of the European Academy of Dermatology and Venereology. 2017;31(9):1401-24. [Crossref]  [PubMed]
  18. Laxer RM, Zulian F. Localized scleroderma. Current opinion in rheumatology. 2006;18(6):606-13. [Crossref]  [PubMed]
  19. Kim J, Chung KB, Lee YI, Kim J, Lee JH. Clinical characteristics and histopathologic changes of morphea: A single-center, retrospective study of 137 patients. Journal of the American Academy of Dermatology. 2021;85(1):105-13. [Crossref]  [PubMed]
  20. Camard M, Maisonobe T, Flamarion E. The groove sign in eosinophilic fasciitis. Clinical Rheumatology. 2022;41(12):3919-20. [Crossref]  [PubMed]
  21. Mertens JS, Seyger MM, Kievit W, et al. Disease recurrence in localized scleroderma: a retrospective analysis of 344 patients with paediatricor adult-onset disease. Br J Dermatol. 2015;172(3):722-728. [Crossref]  [PubMed]
  22. Lebeaux D, Francès C, Barete S, Wechsler B, Dubourg O, Renoux J, et al. Eosinophilic fasciitis (Shulman disease): new insights into diagnosis and management. [PubMed]
  23. Feldman SR, Silver RM, Maize JC. A histopathologic comparison of Shulman's syndrome (diffuse fasciitis with eosinophilia) and the fasciitis associated with the eosinophilia-myalgia syndrome. Journal of the American Academy of Dermatology. 1992;26(1):95-100. [Crossref]  [PubMed]
  24. Weibel L, Laguda B, Atherton D, Harper J. Misdiagnosis and delay in referral of children with localized scleroderma. British Journal of Dermatology. 2011;165(6):1308-13. [Crossref]  [PubMed]
  25. Tollefson MM, Witman PM. En coup de sabre morphea and Parry-Romberg syndrome: a retrospective review of 54 patients. Journal of the American Academy of Dermatology. 2007;56(2):257-63. [Crossref]  [PubMed]
  26. Orozco-Covarrubias L, Guzmán-Meza A, Ridaura-Sanz C, Carrasco Daza D, Sosa-de-Martinez C, Ruiz-Maldonado R. Scleroderma 'en coup de sabre' and progressive facial hemiatrophy. Is it possible to differentiate them?. J Eur Acad Dermatol Venereol. 2002;16(4):361-366. [Crossref]  [PubMed]
  27. Mansour M, Li Wong C, Zulian F, Li S, Morishita K, Yeh EA, et al. Natural history and extracutaneous involvement of congenital morphea: Multicenter retrospective cohort study and literature review. Pediatric dermatology. 2018;35(6):761-8. [Crossref]  [PubMed]
  28. Succaria F, Kurban M, Kibbi AG, Abbas O. Clinicopathological study of 81 cases of localized and systemic scleroderma. Journal of the European Academy of Dermatology and Venereology. 2013;27(2):e191-e6. [Crossref]  [PubMed]
  29. Arkachaisri T, Fertig N, Pino S, Medsger TA Jr. Serum autoantibodies and their clinical associations in patients with childhoodand adult-onset linear scleroderma. A single-center study. J Rheumatol. 2008;35(12):2439-2444. [Crossref]  [PubMed]
  30. Constantin T, Foeldvari I, Pain CE, Pálinkás A, Höger P, Moll M, et al. Development of minimum standards of care for juvenile localized scleroderma. European journal of pediatrics. 2018;177:961-77. [Crossref]  [PubMed]
  31. Ranosz-Janicka I, Lis-Święty A, Skrzypek-Salamon A, Brzezińska-Wcisło L. An extended high-frequency ultrasound protocol for assessing and quantifying of inflammation and fibrosis in localized scleroderma. Skin Res Technol. 2019;25(3):359-366. [Crossref]  [PubMed]
  32. Szczęch J, Samotij D, Jaworecka K, Tobiasz A, Reich A. Quality of Life in Patients with Morphea: A Cross-Sectional Study and a Review of the Current Literature. Biomed Res Int. 2020;2020:9186274. Published 2020 Mar 13. [Crossref]  [PubMed]  [PMC]
  33. Sticherling M. Systemic sclerosis-dermatological aspects. Part 1: pathogenesis, epidemiology, clinical findings. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2012;10(10):705-16. [Crossref]  [PubMed]
  34. Van den Hoogen F, Boerbooms A, Swaak A, Rasker J, Van Lier H, Van De Putte L. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Rheumatology. 1996;35(4):364-72. [Crossref]  [PubMed]
  35. Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 2001;44(6):1351-8. [Crossref]  [PubMed]
  36. Walker KM, Pope J; participating members of the Scleroderma Clinical Trials Consortium (SCTC); Canadian Scleroderma Research Group (CSRG). Treatment of systemic sclerosis complications: what to use when first-line treatment fails--a consensus of systemic sclerosis experts. Semin Arthritis Rheum. 2012;42(1):42-55. [Crossref]  [PubMed]
  37. Farrell A, Dean D, Millard P, Charnock F, Wojnarowska F. Alterations in fibrillin as well as collagens I and III and elastin occur in vulval lichen sclerosus. Journal of the European Academy of Dermatology and Venereology. 2001;15(3):212-7. [Crossref]  [PubMed]
  38. Abbas O, Bhawan J. Sclerosing disorders of the skin: an overview with focus on histopathological features. The American Journal of Dermatopathology. 2014;36(10):763-80. [Crossref]  [PubMed]
  39. Kirtschig G. Lichen sclerosus-presentation, diagnosis and management. Deutsches Ärzteblatt International. 2016;113(19):337. [Crossref]  [PubMed]  [PMC]
  40. Rongioletti F. Lichen myxedematosus (papular mucinosis): new concepts and perspectives for an old disease. Semin Cutan Med Surg. 2006;25(2):100-104. [Crossref]  [PubMed]
  41. Rongioletti F, Rebora A. Mucinoses. In: Bolognia JL, Jorizzo JL, Schaffer JV, editors. Dermatology. 1. 3 ed. Philadelphia: Elsevier Health Sciences; 2012.
  42. Rongioletti F, Merlo G, Cinotti E, Fausti V, Cozzani E, Cribier B, et al. Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients. Journal of the American Academy of Dermatology. 2013;69(1):66-72. [Crossref]  [PubMed]
  43. Satter EK, Metcalf JS, Maize JC. Can scleromyxedema be differentiated from nephrogenic fibrosing dermatopathy by the distribution of the infiltrate? Journal of Cutaneous Pathology. 2006;33(11):756-9. [Crossref]  [PubMed]
  44. Knobler R, Moinzadeh P, Hunzelmann N, Kreuter A, Cozzio A, Mouthon L, et al. European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis. Journal of the European Academy of Dermatology and Venereology. 2017;31(10):1581-94. [PubMed]
  45. Greenberg LM, Geppert C, Worthen HG, Good RA. SCLEREDEMA "ADULTORUM IS" IN CHILDREN: Report of Three Cases with Histochemical Study and Review of World Literature. Pediatrics. 1963;32(6):1044-54. [PubMed]
  46. Meguerditchian C, Jacquet P, Béliard S, Benderitter T, Valéro R, Carsuzza F, et al. Scleredema adultorum of Buschke: an under recognized skin complication of diabetes. Diabetes & metabolism. 2006;32(5):481-4. [Crossref]  [PubMed]
  47. Morais P, Almeida M, Santos P, Azevedo F. Scleredema of Buschke following Mycoplasma pneumoniae respiratory infection. International journal of dermatology. 2011;50(4):454-7. [Crossref]  [PubMed]
  48. Du W, Sun Q-N, Yuan X, Fang K. Clinical and pathologic characteristics of patients with scleredema. Zhongguo yi xue ke xue Yuan xue bao Acta Academiae Medicinae Sinicae. 2009;31(1):42-4. [PubMed]
  49. Galan A, Cowper SE, Bucala R. Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Current opinion in rheumatology. 2006;18(6):614-7. [Crossref]  [PubMed]
  50. Thomsen HS, Morcos SK, Almén T, Bellin M-F, Bertolotto M, Bongartz G, et al. Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines. European radiology. 2013;23:307-18. [Crossref]  [PubMed]
  51. Jain SM, Wesson S, Hassanein A, Canova E, Hoy M, Fennell RS, et al. Nephrogenic fibrosing dermopathy in pediatric patients. Pediatric Nephrology. 2004;19:467-70. [Crossref]  [PubMed]
  52. Deng A, Martin DB, Spillane A, Chwalek J, Surin-Lord S, Brooks S, et al. Nephrogenic systemic fibrosis with a spectrum of clinical and histopathological presentation: a disorder of aberrant dermal remodeling. Journal of cutaneous pathology. 2010;37(2):204-10. [Crossref]  [PubMed]